PCN154 Discussing the Introduction of National Screening Programs in Greece: A Delphi Study  by Skroumpelos, A. et al.
the general public, as it is possible there are differences in the valuation of states
close to death.
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OBJECTIVES:Health-related quality of life is an important issue in the treatment of
breast cancer (BC) and health-state utility values (HSUVs) are essential for cost-
utility analysis. The aim of the study was to identify published values for common
health states for breast cancer and to determine pooled estimates of HSUVs for
each identifiable health state. METHODS: A systematic review of HSUVs for condi-
tions relating to BC was undertaken. Thirteen databases were searched in March
2009. HSUVs were allocated to six categories: screening related states, preventative
states, adverse events in breast cancer and its treatment, non-specific breast can-
cer, early breast cancer (EBC) states and metastatic breast cancer (MBC) states.
Where appropriate meta analysis was used to provide utilities based on combining
all available evidence. Mean utility estimates were pooled using ordinary least
squares with utilities clustered within study group and weighted by both number
of respondents and inverse of the variance of each utility. Regressions included
controls for disease state, utility assessment method and other features of study
design. RESULTS: Forty-nine articles were identified, providing 476 unique utility
values. From these, 117 values for MBC and 230 values for EBC were extracted and
analysed by regression analysis. Utilities were found to vary significantly by valu-
ation method (e.g. in EBC standard gamble had higher valuations than TTO and
EQ-5D), and source of values. For MBC values significantly varied in expected di-
rection by severity of condition, treatment and side-effects. CONCLUSIONS: De-
spite the numerous studies it was not feasible to generate a definitive list of HSUVs
that could be used in future economic evaluations, due to the complexity of the
health states involved and the variety of methods used to obtain values. Future
research into quality of life in BC should make greater use of validated generic
preference-based measures for which public preferences exist.
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WILLINGNESS TO PAY FOR A REDUCTION IN RISK OF TREATMENT SIDE
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OBJECTIVES: The objective of this analysis was to assess patients’ willingness to
pay (WTP) for a reduction in risk of breast cancer treatment side effects.METHODS:
A survey was developed using continent valuation processes to assess the WTP for
a reduction in side effects. The survey asked female MBC patients to provide the
amount they were willing to pay for a 25%, 50% and 100% reduction in risk of the
following side effects: diarrhea/dehydration, hair loss, fatigue, nausea, neutrope-
nia/febrile neutropenia, pain and tingling in hands and feet. Patients were also
asked to select the side effect they would pay the most to avoid. Demographic
information such as age, race/ethnicity, region, employment status, insurance
type, and treatment regimen was also collected. RESULTS:A total of 202 metastatic
breast cancer patients completed the survey. The majority of respondents were
white, married, over the age of 51, and well educated. Most respondents had pri-
vate insurance (67%) or Medicare (24%). Of those who reported paying out of pocket
for their last treatment (58%), the average payment was $459. For a 25%, 50%, and
100% reduction in the risk of side effects, respondents were willing to pay an extra
$1886, $3837 and $7794, respectively. Hair loss (28%), pain (17%) and nausea (15%)
were selected most often as the side effect respondents would pay the most to
avoid. CONCLUSIONS: Patients with MBC highly value reduction in treatment side
effects and are WTP 4.2 times more for a treatment devoid of side effects over a
treatment with a 25% reduction in the risk of side effects. Additional research is
warranted to quantify WTP for specific side effects.
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OBJECTIVES: As outcomes research is being used to inform the decision-maker
about continuation of reimbursement of expensive hospital drugs in the The Neth-
erlands since 2006, this type of research is becoming more important. Our study
started before 2006 and aimed to evaluate therapies in daily clinical practice and
their costs and outcomes. This study gives an indication of the challenges that may
arise from the design of outcomes research.METHODS:An observational follow-up
study was performed including 160 patients with chronic lymphocytic leukemia
(CLL). Data collection on treatment, costs and outcome was performed in 19 Dutch
hospitals using medical records. RESULTS: Patients diagnosed between 1999 and
2003 were included and followed during 6.4 years on average. The mean age was 63
years (range: 30-86). 20% received one therapy-line, 12% two and 24% received three
or more therapy-lines. Most patients received chlorambucil (87%) as first therapy
and the second line was dominated by fludarabine (46%). However, therapies from
the third line onwards varied extensively. Due to the development of new medi-
cines like monoclonal antibodies, the treatment sequence changed in the more
recently diagnosed patients. As a consequence of the relatively low incidence of
CLL and the variety in therapy, the number of patients with comparable therapies
was small. CONCLUSIONS:Management of CLL varied strongly especially after the
second therapy-line. This may be caused by the introduction of monoclonal anti-
bodies as first and second line treatment during the study period. Additionally, a
comparison of alternative therapies was hampered due to relative small number of
patients. Consequently, modeling studies or patient registrations might be neces-
sary to obtain valid information about cost-effectiveness of new expensive inpa-
tient medicines in (chronic) diseases with a low incidence rate and a highly variable
or changing management strategy.
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OBJECTIVES: Controversy continues about screening mammography, partially be-
cause of risks involved. Pre-test breast cancer risk prediction may improve positive
and negative predictive value of screening mammography, particularly among
women who have an abnormal screening mammogram. METHODS: We modeled
one-year breast cancer risk in women with abnormal screening mammograms
(BI-RADS3, BI-RADS4) by combining estimates of pre-test breast cancer risk based
upon established risk factors, 12 validated SNPs and the average probability of
cancer given BI-RADS category. We examined the degree to which the incorpora-
tion of pre-test breast cancer risk would reclassify women from current recom-
mendations for short-term follow up of BI-RADS3 and biopsy of BI-RADS4 using
biopsy thresholds of 1, 2 and 3% probability of breast cancer. RESULTS: Women
with BI-RADS3 in the lowest 5% of pre-test breast cancer risk had a one-year aver-
age breast cancer risk of 0.24% compared to 2.7% for women in the highest 5% of
pre-test risk. Women with BI-RADS4 in the lowest 5% of pre-test risk had a one-year
average breast cancer risk of 4.9% compared to 39.8% for women in the highest 5%
of pre-test risk. Incorporating BI-RADS 4 subclassifications increased the risk dis-
crimination, women with BI-RADS 4A in the lowest 5% of pre-test probability had a
one-year breast cancer risk of 1.4%. Using a biopsy risk threshold of 2%, 8% of
women with a BI-RADS3 had a post-test risk above the threshold for biopsy and 7%
of women with BI-RADS4A had a post-test risk below the threshold.
CONCLUSIONS: Although incorporation of pre-test risk estimates changes deci-
sions about management of abnormal mammograms for a relatively small propor-
tion of women, the public health impact could be significant given the incidence of
abnormal mammograms. Prospective studies are needed to determine effective-
ness of breast cancer risk prediction in improving the positive and negative pre-
dictive value of mammography screening.
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OBJECTIVES: Although cancer morbidity is lower than cardiovascular or metabolic
diseases, it is still the second leading cause of mortality and also the major eco-
nomic problem due to high cost of treatment. According to estimations by the
Karolinska Institutet and Stockholm School of Economics, the direct costs of caring
for cancer patients are approximately 6.5% of total healthcare costs. The aim of this
study was to estimate cost of hospital care in population of patients with neo-
plasms in 2009. METHODS: We used National Health Fund (NHF) statistics on Di-
agnosis-Related Groups (DRGs) attrition in 2009 year. Precise, in respect to ICD-10
diagnosis, NHF statistics cover 85% of all data. We identified data only for malig-
nant neoplasms (C00-C97), in situ neoplasms (D00-D09) and neoplasms of uncer-
tain or unknown behavior (D37-D48). Values are presented in Euro (exchange rate:
1 EUR4.00 PLN). RESULTS: Cost of hospital care in population of patients with
neoplasms was estimated to amount of 246.3 million EUR (289.7 million EUR when
correction for 85% statistics cover will be applied). The highest costs of hospital
care were related to malignant neoplasm of bronchus and lung (34.3 million EUR)
followed by malignant neoplasm of bladder (26.5 million EUR), and malignant neo-
plasm of colon (22.8 million EUR). Given the number of cancer patients in Poland
which is estimated to be 270 thousands, cost of hospital care per cancer patient per
year would be approximately 1073 EUR. However apart from DRGs, cost of hospital
care in population of patients with neoplasms includes also separately contracted
chemotherapy (374.3 million EUR) and some Therapeutics Programs with a new
drugs such as trastuzumab in breast cancer (46.1 million EUR) . CONCLUSIONS:
Cost of hospital care in population of cancer patients is substantial and account for
over 11.5% of all costs of hospital care in Poland in 2009.
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DISCUSSING THE INTRODUCTION OF NATIONAL SCREENING PROGRAMS IN
GREECE: A DELPHI STUDY
Skroumpelos A, Pavi E, Kyriopoulos J
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OBJECTIVES: In the absence of national screening programs (NSP) for adults in
Greece, the aim of this study was to examine experts’ views and recommendations
on a predefined set of NSPs METHODS: A systematic review was conducted to
identify those screening programs that best meet the criteria of clinical effective-
ness and cost efficiency. The programs identified were set for evaluation in a multi-
professional expert panel which completed a structured questionnaire in three
rounds, using the Delphi method. Experts’ agreement was investigated as well as
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their recommendations for the implementation, the target-group, the rescreening
interval and the primary screening methods of the programs proposed, and to
recommend the social insurance reimbursement level. RESULTS:Of the 33 experts
invited, 26 (78%) accepted to participate. The vast majority of them supported the
implementation of an NSP for breast cancer, cervical cancer, colorectal cancer,
vascular risk and abdominal aortic aneurysm. Both the rescreening interval and
the primary screening method of each of the programs were considered adequately
effective. The biggest debate was focused on the target-group of the colorectal
cancer and the abdominal aortic aneurysm program. All of the experts argued that
social insurance should fully reimburse the programs for the individuals that fulfill
the eligibility criteria. Otherwise the cost should be borne by the individual, accord-
ing to the 77% of the panelists. 68% of the experts argued that when the eligibility
criteria are not fullfiled but the individual is referred by a general practitioner or a
specialist for screening, social insurance should partly reimburse the cost.
CONCLUSIONS: Despite any debates especially on the target-group of the pro-
grams, all of the programs were deemed necessary, stressing the need for orga-
nized screening in order to reduce mortality and morbidity from certain conditions
and to optimize the allocation of resources invested in secondary prevention
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OBJECTIVES: To systematically review the literature for methods of estimating the
costs of palliative care and to assess which costs are included in palliative care.
METHODS: Preliminary scoping of health technology assessment appraisals iden-
tified high degree of heterogeneity in how palliative care is defined, in terms of the
type of care, and the models and settings of delivery. To focus the review, patients
with metastatic renal cell carcinoma (mRCC) were chosen as the reference popu-
lation, in keeping with the PICO (population, indication, comparison, outcome)
approach to formulating research questions. Relevant search terms were identified
and searches conducted in EMBASE, MEDLINE, Cochrane library and Econlit. Re-
sults were filtered using pre-specified selection criteria and data extracted into a
pre-defined template. RESULTS: Without a specified patient population, database
searches identified almost 17,000 records; mRCC focussed searches identified 1,172
records. From mRCC searches 66 full text publications were assessed and only 17
met pre-defined inclusion criteria. Of these publications, nine assessed surgery
costs; five were cost-effectiveness assessments; and three assessed burden of dis-
ease. Cost data collected was largely based on expert opinion and country-specific
assumptions (with potential bias) making generalisation difficult. Notable levels of
heterogeneity between the included publications (publication type, year, country
and perspective) precluded consistent, qualitative synthesis of the data.
CONCLUSIONS: Despite focussing on a specific disease population, high levels of
heterogeneity in the reporting and study of palliative care, in terms of setting and
delivery, prevented a robust interpretation of the data. A key driver of this hetero-
geneity may be the fact that palliative care is delivered in a variety of settings, using
diverse models of care. Evidence-based assessments of costs of palliative care
present methodological challenges. Therefore, we see a need for agreement on the
definitions and parameters of palliative care, which would greatly assist future
decision making.
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OBJECTIVES: Australia has the highest incidence of melanoma in the world, how-
ever little published information exists regarding treatment patterns. A study was
undertaken to define current treatment options offered to Australian patients.
METHODS:A survey was developed from interviews with 7 scientific experts treat-
ing melanoma in Australia. Algorithms outlining referral and treatment patterns
across all stages of melanoma were derived and validated by dermatologists and
general surgeons for early stage and medical oncologists for later stage disease.
RESULTS: A total of 115 oncologists were identified as treating melanoma in Aus-
tralia and 26% of those responded. In addition, a sample of 40 dermatologists and
surgeons were contacted and 43% of those participated. Results demonstrated that
nearly all patients with local or locoregional melanomas undergo radical excision
of their primary lesion; whereas 73.1% of patients with metastatic melanoma have
their primary lesion excised. For metastatic disease, the majority of oncologists
reported that current 1st line chemotherapy is dacarbazine (DTIC) (85%) or fote-
mustine (77%), although a large percentage also reported enrolling patients in clin-
ical trials (73%). Nine oncologists (36%) surveyed indicated that they expect overall
survival (OS) of 7-9 months after initiation of 1st line chemotherapy. Oncologists
also reported that 48% of patients who relapse after 1st line therapy receive 2nd
line therapy, of which enrollment into a clinical trial (69%) or treatment with fote-
mustine (62%) are the most common treatment options. Approximately half (48%)
of oncologists surveyed expect OS in 2nd line to be 3-6 months. The most common
sites for development of metastases were reported to be lung (48.0%), liver (47.6%)
and brain (38.0%). CONCLUSIONS: To our knowledge, this is the first survey con-
ducted to understand melanoma treatment patterns in Australia. This study pro-
vides information for evidence-based decision makers to understand how health
resources are utilised in the treatment of melanoma in Australia.
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OBJECTIVES: Access to innovative medicines is sometimes challenging due to is-
sues related to affordability, attributable at least in part to the heterogeneity and
design of health insurance coverage. A support program (Program) to help patients
requesting assistance in accessing oral oncology agents was evaluated to deter-
mine if it facilitated their access to medication.METHODS: Anonymized data from
a random sample of patients enrolling in the Program in 2008-2009 and a random
sample of control patients from Risk Evaluation and Mitigation Strategies (REMS)
programs for lenalidomide and thalidomide were analyzed. Specifically, patient
characteristics, type of assistance provided, and dispensing outcomes (proportion
successfully dispensed medication, time from prescription authorization to first
dispense, reason for non-dispense, and proportion of Program patients seeking
further assistance following their initial request) were assessed. RESULTS: A ran-
dom sample of 1000 Program and 1000 control patients was evaluated. Most pa-
tients had a primary diagnosis of multiple myeloma or of myelosdysplastic syn-
dromes. Despite the expressed need for assistance in accessing medication among
the Program patients, the percentage of Program patients receiving medication
compared with patients in the control group was not statistically different (89% vs.
91%, respectively; p 0.270), with a difference in median time to dispense of 3 days.
Ninety-two percent of Program patients successfully obtained durable access to
oral medication. CONCLUSIONS: The results suggest that a support program for
patients needing assistance in a complex health insurance environment can effec-
tively achieve a goal of helping them to obtain access to therapies prescribed by
their physicians. Research should be conducted to better understand which ele-
ments of such programs are most valuable to patients, and therefore would be
considered best practices for such programs.
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OBJECTIVES: As the potential role of genetic testing in disease prevention and
management grows, so does concern about differences in uptake of genetic testing
across social and racial groups. Characteristics of how genetic tests are delivered
may influence willingness to undergo testing and potentially alter disparities in
testing. METHODS: Conjoint analysis study of the effect of three characteristics of
genetic test delivery on willingness to undergo genetic testing for cancer risk. Data
were collected using a random digit dialing survey of 337 individuals living in the
US. Measures included conjoint scenarios, health care system distrust (values and
competence subscales), health insurance coverage, and sociodemographic charac-
teristics. Three attributes were studied: disclosure of test results to the health
insurer, provision of the test by a specialist or primary care doctor, race specific or
race neutral marketing. RESULTS: In adjusted analyses, disclosure of test results to
insurers, having to get the test from a specialist, and race specific marketing were
all inversely associated with willingness to undergo the genetic test, with the great-
est effect for the disclosure attribute. Racial differences in willingness were not
statistically significant (p0.07) and the effect of the attributes on willingness to
undergo testing did not vary by patient race. However, the decrease in willingness
with insurance disclosure was greater among individuals with high values distrust
(p0.03) and the decrease in willingness to undergo testing from specialist access
was smaller among individuals with high competence distrust (p0.03).
CONCLUSIONS: Several potentially modifiable characteristics of how genetic tests
are delivered are associated with willingness to undergo testing. The effect of two
of these vary according to the level of health care system distrust, suggesting that
policy decisions about delivery of genetic testing may influence differences in up-
take across patient subgroups defined by levels of distrust rather than by race.
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DIAGNOSTICS AND TREATMENT OF PATIENTS WITH NON-SMALL-CELL LUNG
CANCER IN DAILY PRACTICE
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OBJECTIVES: Lung cancer is the most common cause of cancer mortality in Europe.
Gefitinib and erlotinib are two epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) registered for patients with non–small-cell lung cancer
(NSCLC). Patients with a positive EGFR-mutation benefit from first line treatment
with EGFR-TKIs. However, since worse outcomes are observed among patients
without the mutation, testing is crucial. Our study aims to investigate the use of
diagnostics and treatment with EGFR-TKI of patients with NSCLC in daily practice.
METHODS: We sent a semi-structured questionnaire to physicians and laborato-
ries about EGFR-mutation tests and treatment strategies. Furthermore, sales num-
bers of gefitinib and erlotinib were obtained to calculate the number of patients
treated with EGFR-TKI. RESULTS: Response covered more than two third of the
Dutch lung cancer population. Approximately 70% of the patients, which should
have been tested for EGFR-mutation, were tested. Sub-analyses revealed large re-
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